Results 221 to 230 of about 93,603 (306)
Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response. [PDF]
Baune BT +4 more
europepmc +1 more source
Abstract Schatzker type III tibial plateau fractures, characterized by a pure depression of the lateral articular surface, predominantly affect osteoporotic, middle‐aged, and elderly patients. Successful management requires anatomical reduction and stable fixation to minimize complications like post‐traumatic arthritis.
Renbang Huang +3 more
wiley +1 more source
Role of Genetic and Epigenetic Biomarkers in Treatment-Resistant Depression: A Literature Review. [PDF]
Sulić P +5 more
europepmc +1 more source
ABSTRACT Irritability is a prevalent and impairing feature associated with autism, yet remains poorly understood, particularly in adults. Drawing heavily on insights translated from pediatric and transdiagnostic literatures, we propose that irritability in autistic individuals often reflects a psychophysiological stress or threat response, rooted in a ...
Hsiang‐Yuan Lin +3 more
wiley +1 more source
Editorial: Treatment resistant depression (TRD): epidemiology, clinic, burden and treatment
Andrea Fiorillo +3 more
doaj +1 more source
Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression. [PDF]
Patarroyo-Rodriguez L +4 more
europepmc +1 more source
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source

